What is PIRS's revenue growth forecast for 2024-2024?
(NASDAQ: PIRS) Pieris Pharmaceuticals's forecast annual revenue growth rate of -29.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Pieris Pharmaceuticals's revenue in 2024 is $40,927,000.
In 2024, PIRS is forecast to generate $8,753,191 in revenue, with the lowest revenue forecast at $8,753,191 and the highest revenue forecast at $8,753,191.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.